Market Closed -
Japan Exchange
02:00:00 2024-05-01 am EDT
|
5-day change
|
1st Jan Change
|
259
JPY
|
+5.28%
|
|
+9.75%
|
+37.77%
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,439
|
-
|
-
|
Enterprise Value (EV)
1 |
10,439
|
10,439
|
10,439
|
P/E ratio
|
-112
x
|
-7.69
x
|
-7.69
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.9
x
|
-
|
-
|
EV / Revenue
|
14.9
x
|
-
|
-
|
EV / EBITDA
|
-11
x
|
-8.25
x
|
-8.09
x
|
EV / FCF
|
-123
x
|
-11.6
x
|
-8.03
x
|
FCF Yield
|
-0.81%
|
-8.62%
|
-12.5%
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,304
|
-
|
-
|
Reference price
2 |
246.0
|
246.0
|
246.0
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net sales
1 |
700
|
-
|
-
|
EBITDA
1 |
-950
|
-1,265
|
-1,290
|
EBIT
1 |
-85.1
|
-1,275
|
-1,300
|
Operating Margin
|
-12.16%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-79
|
-1,275
|
-1,300
|
Net income
1 |
-80
|
-1,275
|
-1,300
|
Net margin
|
-11.43%
|
-
|
-
|
EPS
2 |
-2.190
|
-32.00
|
-32.00
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
FCF margin
|
-12.13%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024 Q4
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
13.23
|
Dividend per Share
|
-
|
Announcement Date
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
1 |
10
|
10
|
10
|
Capex / Sales
|
1.43%
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Average target price
760
JPY Spread / Average Target +208.94% Consensus |
1st Jan change
|
Capi.
|
---|
| +37.77% | 62.97M | | +0.36% | 42.19B | | +44.30% | 40.15B | | -6.20% | 28.31B | | +5.83% | 24.63B | | -24.41% | 18.2B | | +26.93% | 12.01B | | -3.17% | 11.76B | | +10.88% | 10.4B | | -1.64% | 9.94B |
Other Biotechnology & Medical Research
|